See Bull Run's current market pages for Dr Reddy's Laboratories and Divi's Laboratories. Investors can also compare Divi's with a specialty-pharma giant in Bull Run's Sun Pharma vs Divi's Laboratories comparison.

Q1 FY27 economics: the smaller company generated more operating profit

The first mistake is calling both companies API manufacturers

Dr Reddy's does manufacture APIs and pharmaceutical services.

But its Pharmaceutical Services and Active Ingredients segment generated only approximately ₹852 crore of Q1 revenue.

Total consolidated revenue was ₹8,071 crore.

That means the large majority of Dr Reddy's economics come from commercial pharmaceutical products rather than standalone API manufacturing.

Global Generics represented 89% of Dr Reddy's revenue

The segment includes businesses across:

• North America;
• India;
• Emerging Markets;
• Europe;
• biologics;
• other formulation products.

Dr Reddy's therefore earns from commercialising medicines rather than simply manufacturing ingredients for other companies.

Commercial ownership creates greater upside—and greater volatility

If Dr Reddy's launches a limited-competition generic with strong pricing, it captures much of the commercial economics.

If competition arrives, it also absorbs the price erosion.

The same applies to branded products.

Successful brands can earn attractive margins for years.

But the company must fund sales representatives, promotion, regulatory filings and distribution.

Divi's sits deeper inside the manufacturing chain

In Custom Synthesis, Divi's manufactures intermediates or APIs for pharmaceutical customers whose own drugs may still be in development or already commercial.

The customer's brand can be sold globally without Divi's needing to build a global physician sales force.

Divi's instead competes through chemistry and manufacturing.

That removes one layer of commercial risk

Divi's does not usually need to decide how much to spend promoting a customer's drug to doctors.

It does not negotiate pharmacy formulary access in the same way a branded pharmaceutical company does.

Its focus is on:

• manufacturing yield;
• process chemistry;
• purity;
• regulatory compliance;
• backward integration;
• on-time delivery;
• customer confidentiality;
• capacity availability.

But Divi's still carries drug-programme risk indirectly

If a customer molecule fails in clinical trials, the future manufacturing programme can disappear.

If the customer's drug loses market share, manufacturing volume can decline.

If customer regulatory approval is delayed, Divi's new capacity can sit underutilised.

So Custom Synthesis removes commercial marketing risk but not pharmaceutical development risk entirely.

Divi's Q1 margin was exceptional even by its own standards

EBITDA increased 72.2% to approximately ₹1,255 crore.

EBITDA margin expanded from around 30.2% to 40.8%.

That is an extraordinary manufacturing margin.

The improvement reflected favourable product mix, operating leverage and strong Custom Synthesis contribution.

Do not assume 40.8% is the permanent margin

Large manufacturing campaigns can be produced and shipped in batches.

A quarter containing more high-value Custom Synthesis revenue can therefore produce unusually strong profitability.

Management continued to target double-digit full-year growth rather than extrapolating Q1's exceptional margin and growth rates.

Dr Reddy's Q1 margin was exceptional in the opposite direction

Its 12.5% EBITDA margin should also not be treated as permanent.

The quarter absorbed several adverse effects simultaneously:

• lower lenalidomide contribution;
• ₹239.7 crore semaglutide-API provision;
• generic price erosion;
• higher solvent costs;
• Middle East freight disruption;
• higher SG&A.

Excluding the semaglutide provision alone, EBITDA margin would have been approximately 15.4%.

The comparison therefore captures two extremes

Divi's had an unusually strong mix quarter.

Dr Reddy's had an unusually weak product and cost quarter.

The 40.8% versus 12.5% margin gap is real for Q1.

It should not be used as a permanent normalized gap without adjustment.

The semaglutide issue creates a particularly relevant API lesson

Dr Reddy's found certain batches of semaglutide out of specification because of an API-related issue.

The resulting provision cost ₹239.7 crore.

The episode demonstrates how upstream manufacturing quality can affect a downstream formulation company.

One API issue can create:

• inventory write-downs;
• supply interruption;
• lost sales;
• remediation cost;
• regulatory complexity.

Dr Reddy's own PSAI economics were hit particularly hard

The Pharmaceutical Services and Active Ingredients business generated approximately ₹852 crore of Q1 revenue and grew 4%.

Reported PSAI gross margin was only around 4.5%.

Management estimated PSAI gross margin at approximately 12.9% excluding the semaglutide API effect.

This figure should not be directly compared with Divi's 40.8% EBITDA margin because one is segment gross margin and the other is company EBITDA margin.

But it highlights the scale of the Q1 API-related disruption.

Divi's backward integration is designed to reduce exactly this type of risk

Divi's manufactures several key starting materials and intermediates internally.

This helps improve:

• supply assurance;
• quality control;
• cost visibility;
• process consistency;
• manufacturing efficiency.

Backward integration is one reason the company can support demanding global innovator customers.

It also creates a very different gross-margin profile

Divi's Q1 standalone material consumption was around 31.2% of revenue from operations.

This reflected both favourable mix and the benefits of integrated manufacturing.

Dr Reddy's consolidated gross margin was 46.5%, meaning cost of revenue absorbed more than half of sales before SG&A and R&D.

The difference is partly business mix rather than manufacturing competence alone.

Dr Reddy's spends heavily to commercialise products

SG&A represented 35.7% of revenue.

R&D represented another 7.1%.

These costs support:

• physician marketing;
• branded portfolios;
• regulatory filings;
• innovative products;
• market access;
• sales infrastructure;
• future pipelines.

Divi's does not carry an equivalent global commercial cost structure.

That is why revenue multiples alone are misleading

Dr Reddy's generates much more revenue because it captures downstream commercial sales.

Divi's sells less revenue but retains a larger percentage as manufacturing profit when product mix is favourable.

Neither model is inherently superior.

They create value through different bottlenecks in the pharmaceutical value chain.

Dr Reddy's diversification is much greater

Q1 revenue included approximately:

• ₹2,205 crore North America;
• ₹1,833 crore Emerging Markets;
• ₹1,718 crore India;
• ₹1,444 crore Europe;
• ₹852 crore PSAI;
• other businesses.

No single market represented half of consolidated revenue.

Branded businesses represented 52%

Dr Reddy's India, Emerging Markets and acquired nicotine-replacement portfolio together represented around 52% of Q1 revenue.

This is strategically important because branded businesses can generate more durable customer relationships than commodity generics.

The company is slowly reducing dependence on US generic exclusivity economics.

Divi's geographic exposure is concentrated differently

Exports represented approximately 90% of standalone revenue.

Europe and North America together represented about 75% of exports.

Divi's therefore has heavy international exposure even though it does not own the consumer-facing brands sold in those markets.

Currency, customer inventory and global pharmaceutical demand still matter.

Divi's customer relationships can be exceptionally sticky

Once an innovator customer validates a manufacturing process and includes a supplier in regulatory documentation, changing the supplier can require meaningful time and regulatory work.

That creates switching costs.

For successful commercial medicines, a reliable manufacturing relationship can therefore last for many years.

Three major Divi's projects are approaching validation

Management said three major capex programmes were nearing completion, with validation work underway.

These projects support future Custom Synthesis opportunities.

Validation is an important milestone.

But it is not the same as commercial revenue.

Customers and regulators must still complete relevant approval processes.

Divi's has ₹2,034 crore of capital work in progress

At June 30, 2026, capital work in progress was approximately ₹2,034 crore.

The company capitalised around ₹451 crore of assets during Q1.

This demonstrates the scale of the manufacturing expansion underway.

The investment case depends on those assets reaching high utilisation.

Peptides are one of Divi's most important next growth markets

Peptide medicines are growing rapidly across metabolic and other therapeutic categories.

Manufacturing them at scale is technically complex.

Divi's is expanding both solid-phase and liquid-phase synthesis capability.

This plays directly into its strengths in process chemistry and high-volume manufacturing.

Dr Reddy's is also targeting peptides—but downstream

Dr Reddy's R&D remains focused on complex products including peptides.

It launched generic semaglutide injection in Canada and semaglutide tablets in India during Q1.

This illustrates the value-chain difference.

Divi's opportunity is to manufacture complex peptide ingredients.

Dr Reddy's opportunity is to turn complex molecules into approved finished products and commercial brands.

Both can win from the same pharmaceutical trend

Increasing global peptide demand can create value for:

• API manufacturers;
• intermediate manufacturers;
• finished-dose manufacturers;
• device suppliers;
• commercial pharmaceutical companies.

The economics are distributed across the chain.

Dr Reddy's R&D creates larger product optionality

Q1 R&D spending was approximately ₹577 crore.

The pipeline includes complex generics, biosimilars, peptides and innovative partnered assets.

One successful global differentiated product can create a very large commercial revenue opportunity.

But this spending also creates failure risk.

Divi's process R&D carries different risk

Divi's mainly needs to solve chemistry, process and scale-up problems.

It generally does not fund Phase III clinical trials for the end drug in the same way an innovator does.

That reduces binary clinical risk.

Its dependency shifts toward customer programme success and manufacturing execution.

Divi's balance sheet is exceptionally clean

Bull Run's standardized debt-to-equity field is effectively zero.

Divi's reported approximately ₹3,611 crore of cash and cash equivalents at the end of Q1.

This gives it substantial capacity to fund the capex programme internally.

Dr Reddy's also has a net-cash surplus

Management reported approximately ₹3,060 crore of net cash surplus at June 30.

Gross cash, cash equivalents and investments were much larger, while borrowings reflected acquisition and financing activities.

Both companies therefore enter their next investment cycles with manageable balance sheets.

Divi's current ROCE is higher

Divi's currently leads on ROCE and ROE.

Dr Reddy's has produced substantially more cumulative free cash flow over five years because it operates at much greater scale.

This demonstrates again that percentage quality and absolute cash generation tell different stories.

Dr Reddy's Q1 company-reported ROCE was much lower than its trailing ratio

Management calculated annualised Q1 ROCE at 5.3%.

Excluding the semaglutide API issue, it was approximately 8%.

Bull Run's trailing standardized ROCE remains around 14.8% because it captures a longer earnings period.

The Q1 figure illustrates how sharply current profit fell.

Divi's current margin creates tremendous operating leverage

At a 40% EBITDA margin, every additional ₹100 crore of similarly profitable revenue can potentially produce far more EBITDA than a lower-margin commercial pharmaceutical model.

But the important phrase is similarly profitable.

If future product mix shifts toward generic APIs, incremental margin can be lower.

Valuation is the strongest argument for Dr Reddy's

Divi's trades at more than twice Dr Reddy's trailing P/E.

Its price-to-book multiple is more than four times Dr Reddy's.

The market is clearly paying for:

• higher margins;
• faster growth;
• Custom Synthesis;
• debt-free balance sheet;
• peptide optionality;
• manufacturing execution.

Divi's one-year rerating raises the execution hurdle

Bull Run's September snapshot shows Divi's up approximately 50% over one year.

Dr Reddy's is down approximately 8.5%.

That creates very different expectation levels.

Divi's needs continued earnings growth to justify a 66x multiple after a large rerating.

Dr Reddy's needs a credible operating recovery.

Dr Reddy's lower valuation is not automatically cheap

The company's current Q1 earnings are far below the trailing profit used in the P/E denominator.

If EBITDA remains near 12–15%, trailing earnings will fall further as stronger historical quarters roll out.

The current P/E therefore assumes recovery to some extent.

Divi's higher valuation also assumes Q1 is not a peak

If Custom Synthesis mix normalises sharply and EBITDA margin returns toward historical low-30s levels, the stock can look much more expensive on forward earnings.

The company therefore needs new projects, peptides and capacity utilisation to sustain earnings momentum.

The two stocks represent almost opposite pharmaceutical bets

What must Dr Reddy's prove?

• Post-lenalidomide North America revenue needs replacement products.
• Semaglutide manufacturing issues must be resolved.
• EBITDA margin must recover materially.
• Branded India and Emerging Markets growth should remain strong.
• Pipeline approvals need commercial conversion.
• Biologics regulatory execution must remain disciplined.
• R&D returns need to improve normalized ROCE.

What must Divi's Laboratories prove?

• Custom Synthesis growth must remain strong beyond one exceptional quarter.
• New capex programmes need successful customer validation.
• Peptide investments should create commercial revenue.
• Generic API pricing pressure must remain manageable.
• Capacity expansion should preserve 20%-plus ROCE.
• Customer concentration needs continued diversification.
• Margins need to remain strong enough to justify a 66x P/E.

What could make Dr Reddy's outperform Divi's?

A normalized earnings recovery combined with valuation compression at Divi's.

If Dr Reddy's EBITDA margin returns materially above Q1 while Divi's margin normalises, the earnings-growth gap can narrow rapidly.

Dr Reddy's starts from a much lower valuation multiple.

What could make Divi's outperform Dr Reddy's?

Successful conversion of major Custom Synthesis and peptide projects.

If new dedicated programmes ramp while margins remain structurally high, Divi's can continue generating extraordinary earnings growth without carrying the same downstream commercial expense base.

Which has the stronger Q1 operating economics?

Divi's Laboratories by a wide margin.

It produced more EBITDA and more than twice the PAT on less than 40% of Dr Reddy's revenue.

Which is more diversified?

Dr Reddy's Laboratories.

Its business spans North America, India, Emerging Markets, Europe, APIs, consumer health, biosimilars and innovative partnered products.

Which has the cleaner balance sheet?

Divi's Laboratories.

Bull Run records essentially zero debt-to-equity, although Dr Reddy's also reports a positive net-cash surplus.

Which has the stronger valuation?

Dr Reddy's.

Its trailing P/E is approximately 31.9x versus Divi's around 66x and its price-to-book multiple is much lower.

Which is better: Dr Reddy's or Divi's Laboratories?

Divi's Laboratories currently has the stronger operating-quality profile. Revenue grew 28%, EBITDA grew more than 70%, PAT grew 66%, Custom Synthesis represented 60% of revenue and Q1 EBITDA margin reached an extraordinary 40.8%.

Dr Reddy's currently has the stronger valuation and diversification profile. Its current earnings are depressed by a product-cycle reset and one-off API provision, but its businesses span multiple geographies, branded medicines, complex generics and emerging pipeline opportunities.

The valuation gap is enormous.

Divi's trades around 66x trailing earnings.

Dr Reddy's trades around 31.9x.

At September 2026 valuations, Divi's is the higher-quality current operator but requires continued exceptional execution. Dr Reddy's is the lower-expectation recovery case: it becomes substantially more attractive if margins normalise while its branded and complex-product pipeline continues growing.

Frequently asked questions